PE $12-5.$ Per the I$2$C$2$ embedded clinics$/$pharmacies $($ECP$)$ business case, I$2$C$2$ is considering a series of enhancements to this

existing system. In planning discussions with I$2$C$2$ business and IT team members, the following points were captured in the

meeting minutes. Complete the following for each of these points: $(1)$ Determine if the item is a risk, and issue, an assumption,

or a constraint. $(2)$ For risks and issues, determine the level of impact $($high$,$ medium, or low$)$ and relate it to a corresponding

item in Table $12-2.(3)$ For risks, determine the level of probability $($high$,$ medium, or low$)$ and your preferred mitigation

strategy $($avoidance$,$ limitation$,$ transference, or acceptance$).$ For each item, explain your answers.

a$.$ Given the dozen countries in which I$2$C$2$ operates clinics$/$pharmacies$,$ management decided to let three senior pharmacy

leaders in Mexico, Ethiopia, and Malaysia be product owners on behalf of the rest of the world.

b$.$ The prior point did raise a concern that those three leaders might not be able to speak for users in the other nine countries,

given differences in legal regulations and market practices in different parts of the world.

c$.$ Further, it was just determined that one of those three senior pharmacy leaders will be going out on paternity leave for two

months.

d$.$ In discussing the $$sharing drugs$$ feature, there was some disagreement regarding whether I$2$C$2$ pharmacies should be able

to share drugs across national borders. In several geographically small countries in Central America, pharmacists noted that

I$2$C$2$ pharmacies in different countries were only a few miles apart. The cost$-$estimation impacts of this could be large.

e$.$ For sharing drugs and consolidated purchasing, the system is currently built with each pharmacy running its own instance of

the system using a local database. This will necessitate implementing a new architecture using a centralized database, either

replacing the existing local databases or maintaining copies of that data.

f$.$ The I$2$C$2$ team has historically underestimated the time and cost needed to develop features. Because of this, the CIO is

requiring improved training on project estimation, planning, and management.

g$.$ Also, the CIO noted that I$2$C$2$ has historically utilized several key outside contractors, each of whom understands the I$2$C$2$

pharmacy system thoroughly. However, because I$2$C$2$ hasn$$t used those contractors for almost a year, it is not clear if they

will be available for this project.

h$.$ This project cannot start for another six weeks, while the development team finishes up another, unrelated project that is

occupying them full$-$time.